₹839.75
▼ -10.29 -1.21%
17 Jul 2026
NSE Listed
Alembic Pharma Ltd. (APLLTD)
Volume: 92,763Avg Vol 1W: 1,26,818.6Avg Vol 1M: 1,59,047.2552W Range:₹635.8₹1,044
Key Ratios
Checked 2h agoMarket Cap₹16,506 Cr
Current Price₹839.75
Previous Close₹850.04
High / Low (52w)₹1,044 / ₹635.8
Volume92,763
Avg Vol (1W)1,26,818.6
Avg Vol (1M)1,59,047.25
Stock P/E81.45
Book Value₹288.7
Dividend Yield143%
ROE11.89%
ROA7.66%
Revenue (TTM)₹6,715 Cr
Revenue Growth7.1%
Profit Margin9.19%
Total Debt₹0 Cr
Shares Outstanding20 Cr
Face Value₹2
EPS (TTM)₹37.18
P/B2.91
Debt / Equity0.25
50 DMA₹776.49
200 DMA₹801.79
Day change-1.21%
Price Chart
₹839.75▼ 18.94% · 1Y
2025-07-172026-07-16
20-day avg volume: 1.6L shares
Pros
- Pays a dividend yield of 143.0%.
- Company is almost debt-free.
Cons
- Revenue fell 16% YoY.
- Stock trades at a high P/E of 81.
Quarterly Results
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,562 Cr | ₹1,648 Cr | ₹1,693 Cr | ₹1,770 Cr | ₹1,711 Cr | ₹1,910 Cr | ₹1,876 Cr | ₹1,848 Cr |
| EBITDA | ₹170 Cr | ₹186 Cr | ₹200 Cr | ₹217 Cr | ₹214 Cr | ₹247 Cr | ₹229 Cr | ₹165 Cr |
| Net Profit | ₹135 Cr | ₹153 Cr | ₹138 Cr | ₹157 Cr | ₹154 Cr | ₹185 Cr | ₹133 Cr | ₹203 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3,138 Cr | ₹3,944 Cr | ₹4,611 Cr | ₹5,480 Cr | ₹5,356 Cr | ₹5,655 Cr | ₹6,257 Cr | ₹6,715 Cr |
| EBITDA | ₹545 Cr | ₹768 Cr | ₹1,071 Cr | ₹1,384 Cr | ₹638 Cr | ₹436 Cr | ₹689 Cr | ₹772 Cr |
| Net Profit | ₹413 Cr | ₹584 Cr | ₹829 Cr | ₹1,147 Cr | ₹521 Cr | ₹342 Cr | ₹616 Cr | ₹583 Cr |
| EPS | 21.89 | 31 | 43.97 | 59.18 | 26.5 | 17.4 | 31.33 | 29.68 |
Balance Sheet
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹3,941 Cr | ₹4,778 Cr | ₹5,989 Cr | ₹6,709 Cr | ₹7,122 Cr | ₹6,183 Cr | ₹6,446 Cr | ₹7,773 Cr |
| Total Liabilities | ₹1,721 Cr | ₹2,060 Cr | ₹2,799 Cr | ₹1,642 Cr | ₹1,884 Cr | ₹1,812 Cr | ₹1,627 Cr | ₹2,583 Cr |
| Equity | ₹2,220 Cr | ₹2,718 Cr | ₹3,190 Cr | ₹5,067 Cr | ₹5,238 Cr | ₹4,370 Cr | ₹4,818 Cr | ₹5,190 Cr |
| Total Debt | — | — | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating | ₹448 Cr | ₹978 Cr | ₹685 Cr | ₹1,709 Cr | ₹676 Cr | ₹785 Cr | ₹823 Cr | ₹159 Cr |
| Investing | ₹-884 Cr | ₹-756 Cr | ₹-732 Cr | ₹-839 Cr | ₹-372 Cr | ₹-448 Cr | ₹-321 Cr | ₹-568 Cr |
| Financing | ₹503 Cr | ₹59 Cr | ₹155 Cr | ₹-597 Cr | ₹-217 Cr | ₹-262 Cr | ₹-438 Cr | ₹444 Cr |
| Free Cash Flow | ₹448 Cr | ₹978 Cr | ₹685 Cr | ₹1,709 Cr | ₹676 Cr | ₹785 Cr | ₹823 Cr | ₹159 Cr |
Shareholding
Promoter 69.74% Institutions 20.43% Public 9.83%
Efficiency & Working Capital
ROCE10.8%
Interest Coverage8.4
Dividend Payout—
Debtor Days73 d
Inventory Days125 d
Payable Days41 d
Cash Conversion Cycle156 d
Working Capital Days198 d
Shareholding Details
As of 2026-06-30
Promoter69.9%
FII4.2%
DII15.9%
Institutions20.1%
Public10%
Promoter Pledge0%
No. of Shareholders86,796
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 69.6% | 69.6% | 69.6% | 69.6% | 69.6% | 69.6% | 69.7% | 69.7% | 69.7% | 69.7% | 69.7% | 69.9% |
| FIIs | 4.5% | 4.5% | 4.5% | 4.3% | 3.9% | 4.2% | 3.9% | 4% | 4% | 4.2% | 4.3% | 4.2% |
| DIIs | 13.9% | 14.5% | 15.4% | 15.5% | 16.1% | 16.1% | 16.4% | 16.5% | 16.3% | 16.2% | 16.2% | 15.9% |
| Public | 12% | 11.4% | 10.5% | 10.6% | 10.4% | 10.2% | 10% | 9.9% | 9.9% | 9.9% | 9.8% | 10% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 89,552 | 85,212 | 76,567 | 74,829 | 91,429 | 93,944 | 91,336 | 89,013 | 89,969 | 87,000 | 86,432 | 86,796 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Nirayu Private Limited | Shareholding of Promoter and Promoter Group | 35.7% | 7.01 Cr |
| Alembic Limited | Shareholding of Promoter and Promoter Group | 28.5% | 5.61 Cr |
| Life Insurance Corporation Of India | Public Shareholding | 4.3% | 84,95,125 |
| Dsp Midcap Fund | Public Shareholding | 4.2% | 83,16,021 |
| Chirayu Ramanbhai Amin | Shareholding of Promoter and Promoter Group | 2.1% | 41,92,529 |
| Tata Aia Life Insurance Co Ltd Unit Linked Multi Cap Fund | Public Shareholding | 1.8% | 35,58,328 |
| Kotak Small Cap Fund | Public Shareholding | 1.7% | 34,27,766 |
| Malika Chirayu Amin | Shareholding of Promoter and Promoter Group | 1.5% | 30,05,730 |
| Icici Prudential Pharma Healthcare And Diaganostics (p.h.d) Fund | Public Shareholding | 1.1% | 22,07,390 |
| Udit Chirayu Amin | Shareholding of Promoter and Promoter Group | 0.5% | 10,06,980 |
| Pranav Chirayu Amin | Shareholding of Promoter and Promoter Group | 0.5% | 10,09,800 |
| Shaunak Chirayu Amin | Shareholding of Promoter and Promoter Group | 0.5% | 10,06,980 |
| Chirayu Ramanbhai Amin Huf | Shareholding of Promoter and Promoter Group | 0.1% | 2,18,295 |
| Gallup Trust (pranav Chirayu Amin) | Shareholding of Promoter and Promoter Group | 0.1% | 1,00,100 |
| Inaaya Shaunak Amin | Shareholding of Promoter and Promoter Group | 0% | 80,000 |
| Naintara Shaunak Amin | Shareholding of Promoter and Promoter Group | 0% | 80,000 |
| Barkha Pranav Amin | Shareholding of Promoter and Promoter Group | 0% | 50,100 |
| Krupa Shaunak Amin | Shareholding of Promoter and Promoter Group | 0% | 50,100 |
| Satori Trust (chirayu Ramanbhai Amin) | Shareholding of Promoter and Promoter Group | 0% | 50,100 |
| Ranvir Pranav Amin | Shareholding of Promoter and Promoter Group | 0% | 30,000 |
| Samira Pranav Amin | Shareholding of Promoter and Promoter Group | 0% | 30,000 |
| Paushak Limited | Shareholding of Promoter and Promoter Group | 0% | 855 |
| Alembic City Limited | Shareholding of Promoter and Promoter Group | 0% | 100 |
| Shreno Publications Limited | Shareholding of Promoter and Promoter Group | 0% | 100 |
| Shreno Engineering Limited | Shareholding of Promoter and Promoter Group | 0% | 100 |
Promoter Pledges
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| Chirayu Ramanbhai Amin | 0 | 0% | 2026-03-31 |
| Chirayu Ramanbhai Amin Huf | 0 | 0% | 2026-03-31 |
| Malika Chirayu Amin | 0 | 0% | 2026-03-31 |
| Pranav Chirayu Amin | 0 | 0% | 2026-03-31 |
| Shaunak Chirayu Amin | 0 | 0% | 2026-03-31 |
| Inaaya Shaunak Amin | 0 | 0% | 2026-03-31 |
| Naintara Shaunak Amin | 0 | 0% | 2026-03-31 |
| Ranvir Pranav Amin | 0 | 0% | 2026-03-31 |
| Samira Pranav Amin | 0 | 0% | 2026-03-31 |
| Barkha Pranav Amin | 0 | 0% | 2026-03-31 |
| Krupa Shaunak Amin | 0 | 0% | 2026-03-31 |
| Alembic Limited | 0 | 0% | 2026-03-31 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Chirayu R Amin | Chairman & Chief Executive Officer | 2025 |
| Rajkumar Baheti | Director (Finance) & Chief Financial Officer | 2025 |
| Pranav Amin | Managing Director | 2025 |
| Shaunak Amin | Managing Director | 2025 |
| Ashok Barat | Independent Director | 2025 |
| Manisha Saraf | Company Sec. & Compli. Officer | 2025 |
| Jai S Diwanji | Independent Director | 2025 |
| Manish Kejriwal | Independent Director | 2025 |
| Geeta Goradia | Independent Director | 2025 |
Segments — Product
| Segment | Revenue | Share |
|---|---|---|
| Pharmaceuticals | ₹0 Cr | — |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2026 | ₹2 | 41 | 39 | 39 |
Corporate Actions
| Type | Date | Value | Remark |
|---|---|---|---|
| forthcoming | 2026-07-29 | Dividend (12/- per share) | Final |
| dividend | 2025-07-29 | ₹11 (550%) | Final |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2026 | 506 | 0 | 0 | 68 | 445 | 1,023 |
| 2026 | 451 | 0 | 0 | 0 | 21 | 472 |
| 2026 | 41 | 0 | 0 | 68 | 423 | 537 |
Insider / Designated-Person Trades
30 recent disclosure(s)
Nirayu Private LimitedAcquisition · 3,278
Nirayu Private LimitedAcquisition · 24,832
Nirayu Private LimitedAcquisition · 75,000
Nirayu Private LimitedAcquisition · 20,000
Nirayu Private LimitedAcquisition · 78,000
Nirayu Private LimitedAcquisition · 60,000
Substantial Acquisitions (SAST)
1 disclosure(s)
Market24/11/2023 · 36,276
Company Information
🌐 www.alembicpharmaceuticals.com ↗
📍 Alembic Road, Vadodara, Gujarat, 390003
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search